Indoco Remedies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indoco Remedies reported Q1 FY26 standalone revenue of ₹383.8 crore, up 12.5% sequentially from ₹341.1 crore in Q4 FY25, but down about 2.6% from ₹394.2 crore in Q1 FY25. Despite the sequential revenue improvement, the company swung to a standalone loss of ₹28.1 crore versus a profit of ₹15.0 crore a year ago, with EPS at ₹(3.04) versus ₹1.62. On a consolidated basis, revenue was ₹429.1 crore versus ₹424.3 crore YoY, with a loss after tax of ₹36.4 crore versus a small profit of ₹1.8 crore earlier. The auditor (Gokhale & Sathe) issued an unmodified opinion but flagged an Emphasis of Matter regarding two subsidiaries — FPP Holding LLC and Warren Remedies Pvt Ltd — both of which have negative net worth and may face going-concern uncertainty, though the parent did not book any impairment.
Negative near-term sentiment likely as the company reported a YoY loss despite stable revenues, driven by higher finance costs and employee/other expenses. However, the sequential revenue recovery, EBITDA improvement to ₹148 mn from ₹35 mn, and the parent's own net worth remaining positive offer some comfort. Investors should watch the parent's exposure to its loss-making subsidiaries, especially FPP Holding and Warren Remedies, as further deterioration there could trigger impairments.